Literature DB >> 17875607

Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.

G Sóczó1, G Kardos, P M McNicholas, E Balogh, L Gergely, I Varga, B Kelentey, L Majoros.   

Abstract

OBJECTIVES: We evaluated the in vitro activity of posaconazole against nine Candida species using minimum fungicidal concentration (MFC) measurements and time-kill methods.
METHODS: MFCs of posaconazole were determined for 209 clinical isolates (32 Candida albicans, 30 Candida glabrata, 21 Candida tropicalis, 29 Candida krusei, 28 Candida parapsilosis sensu stricto, 50 Candida inconspicua, 13 Candida kefyr, 3 Candida lusitaniae and 3 Candida guilliermondii) and 7 ATCC Candida strains. The following strains were tested in time-kill studies: 3 strains each of C. glabrata, C. kefyr, C. guilliermondii and C. lusitaniae; 2 C. tropicalis; 4 C. albicans; 4 C. inconspicua; 9 C. krusei; 12 C. parapsilosis; and 7 ATCC strains.
RESULTS: Posaconazole was fungicidal in both MFC and time-kill experiments (at 2 mg/L within 48 h in time-kill assays) against each C. krusei, C. inconspicua and C. lusitaniae strain and was fungistatic against each C. albicans, C. glabrata, C. tropicalis and C. guilliermondii strain. For the C. parapsilosis strains, posaconazole MFCs were <or=2 mg/L for 20 of the 28 isolates tested; however, in the time-kill tests, even at drug concentrations of 32-64 x MIC, posaconazole was fungistatic against all C. parapsilosis strains tested.
CONCLUSIONS: MFC values were good predictors of the fungistatic or fungicidal activity of posaconazole, as determined by time-kill curves, for all tested species except C. parapsilosis. Our results highlight the fungicidal action of posaconazole against a number of clinically relevant Candida species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875607     DOI: 10.1093/jac/dkm350

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Maria-Ioanna Beredaki; Maiken Cavling Arendrup; David Andes; Johan W Mouton; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades.

Authors:  Zoltán Papp; Andrew M Borman; Lajos Forgács; Renátó Kovács; Zoltán Tóth; Chiu Chun-Ju; Gábor Kardos; Béla Juhász; Judit Szilvássy; László Majoros
Journal:  Pathogens       Date:  2021-08-06

3.  Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.

Authors:  Gulsen Hazirolan; Emilia Canton; Selma Sahin; Sevtap Arikan-Akdagli
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

4.  Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis.

Authors:  Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

5.  Efficacy of triazoles in a murine disseminated infection by Candida krusei.

Authors:  Marçal Mariné; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

6.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

7.  In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B.

Authors:  Yongqin Wu; Marissa Totten; Warda Memon; Chunmei Ying; Sean X Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

8.  Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.

Authors:  Elisabetta Spreghini; Carmelo Massimo Maida; Serena Tomassetti; Fiorenza Orlando; Daniele Giannini; Maria Eleonora Milici; Giorgio Scalise; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  Anti-Candida activity of Quercus infectoria gall extracts against Candida species.

Authors:  Nur Saeida Baharuddin; Hasmah Abdullah; Wan Nor Amilah Wan Abdul Wahab
Journal:  J Pharm Bioallied Sci       Date:  2015 Jan-Mar

Review 10.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.